Technology | Women's Health | November 13, 2017

Biop Medical Launches Cervical Cancer Diagnosis Technology at MEDICA 2017

Mobile device accurately detects cervical cancer in real time

Biop Medical Launches Cervical Cancer Diagnosis Technology at MEDICA 2017

Biop Medical cervical cancer detection system

Biop Medical cervical cancer detection system with high definition digital colposcope module

Biop Medical cervical cancer detection system with micro-colposcope module

November 13, 2017 — Biop Medical announced it will present its point-of-care cervical cancer detection technology at MEDICA 2017 in Düsseldorf, Germany, Nov. 13-16.  The company recently started its second round of investment.

The tool advances cervical cancer diagnosis using optic technology that accurately detects cancerous and pre-cancer lesions in real time. Patients receive an immediate diagnosis without the prolonged waiting time and stress associated with common diagnostic methods. The technology generates a map of diseased lesions to help physicians pinpoint exactly where to perform biopsies.

Biop Medical’s system consists of two components which are connected to the main control unit. The high definition Biop digital colposcope module offers a high-resolution digital cervix visualization. When the Biop micro-colposcope module is connected, it is directed by an algorithm to the centre of the cervix and then performs a thorough high-magnification inner scan of the cervix.

Using a sterile and disposable cover, the device is inserted until it is in contact with the cervix and projects a full array of light into the full depth of the cervix. The received refractions and reflections off the cervical tissue by the emitted light indicate where cancerous and pre-cancerous lesions are located. When used together, the scans from both components create a color map to help physicians determine where to perform biopsies.

This data can help track the cancer's advancement, with results automatically uploaded to the cloud. The platform for aggregating the data was developed with the support of IBM during Biop Medical's time at the IBM Alpha Zone Accelerator.

The technology requires a short and simple training, compared to years of experience required to capably perform cervical cancer diagnosis with a colposcope.

For more information: www.biopmedical.com

Related Content

HealthMyne Highlights Value of Quantitative Data in Oncology Reads at RSNA 2017
News | Clinical Decision Support | November 17, 2017
November 17, 2017 — At the 2017 Radiological Society of North America (RSNA) conference, HealthMyne will demonstrate
Kansas City Radiology Center Employs iCAD PowerLook Tomo Detection for DBT
News | Computer-Aided Detection Software | November 10, 2017
November 10, 2017 — Imaging for Women, a leading radiology center in Kansas City, Mo., announced it is now using iCAD
Kubtec Brings Image Analytics Capabilities to Tomosynthesis Specimen Imaging Systems
News | Mammography | November 10, 2017
Kubtec announced it will be showcasing new image analytics capabilities on its advanced tomosynthesis specimen imaging...
Siemens Healthineers Introduces Share360 Tailored Service Portfolio
News | Imaging | November 10, 2017
November 10, 2017 — To address the specific needs of...
Fujifilm Highlights Women's Health and Pediatrics at RSNA 2017
News | Information Technology | November 08, 2017
November 8, 2017 — Fujifilm Healthcare will showcase a variety of imaging and information technology solutions at the
CureMetrix Expands Medical Advisory Board
News | Computer-Aided Detection Software | November 08, 2017
November 8, 2017 — CureMetrix, a company developing...
ICPME Makes EQUIP Mammography Inspection CME/CE Webinar Available Online
News | Mammography | November 08, 2017
November 8, 2017 — In conjunction with Brea...
Study Suggests Breast Cancer Patients Forego Post-Surgery Treatment Due to Mistrust
News | Radiation Therapy | November 06, 2017
November 6, 2017 — Nearly one-third of women with...
Study shows tissue marker reduces radiation target volumes, produces many other advantages

These CT images show placement of a 3-D fixed array implanted fiducial (3-D marker) at the time of oncoplastic tumor resection. The original LCTV (LCTVo) was retrospectively re-contoured by the radiation oncologist (LCTVro) and breast surgeon (LCTVbs). Thereafter, both re-contours were combined to create the collaborative LCTV (LCTVc), which required agreement of both the radiation oncologist and breast surgeon. Volume differences between the original LCTV (LCTVo) and the collaborative LCTVc were then evaluated, and demonstrated a mean and median reduction in LCTV.

Feature | Tumor Tracking Systems | November 06, 2017 | By William Hall, M.D.
Radiation planning for breast cancer relies on accurate delineation of the post-lumpectomy target volume as identified...
Blood Test Rules Out Breast Cancer Regardless of Density
News | Oncology Diagnostics | November 03, 2017
November 3, 2017 — A new study published in ...
Overlay Init